8-K: Brainstorm Cell Therapeutics Secures $1M in Private Placement

Brainstorm Cell Therapeutics Inc. announced a $1 million private placement and an increase in its stock incentive plan pool.

Summary

• Brainstorm Cell Therapeutics Inc. entered into a Securities Purchase Agreement for a private placement of common stock and pre-funded warrants with an accredited investor.
• The aggregate subscription amount is $1,000,000, with $125,000 received at the first closing on February 24, 2026.
• Up to seven additional closings are planned, totaling an additional $875,000, with the final closing by September 25, 2026.
• The purchase price for common stock is $0.60 per share, and for pre-funded warrants is $0.60 less $0.0005, with a pre-funded warrant exercise price of $0.00005 per share.
• The company will also issue common stock purchase warrants exercisable for 120% of the purchased shares/pre-funded warrants, with an exercise price of $1.00 per share.
• Net proceeds from the sale will be used for working capital purposes.
• The Board of Directors approved an amendment to the 2014 Stock Incentive Plan and 2014 Global Share Option Plan, increasing the shared pool of shares available for issuance by 5,500,000, bringing the total to 8,406,666 shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with a slightly negative sentiment. While the capital raise provides necessary working capital, the significant dilution from the private placement and the substantial increase in the stock incentive plan pool are concerning for existing shareholders.

Positives

• Secured $1,000,000 in capital, providing funds for working capital.
• The private placement structure allows for staged funding, providing flexibility.
• The company is committed to maintaining its listing and registering the resale of securities, which benefits investors.

Negatives

• The issuance of new shares and warrants will result in dilution for existing shareholders.
• The increase in the stock incentive plan pool by 5,500,000 shares (to a total of 8,406,666 shares) represents significant potential future dilution for existing shareholders.
• The purchase price of $0.60 per share/warrant is below the common warrant exercise price of $1.00, indicating a discount for the investor.

Risks

• The investor's hedging activities (including short sales or derivative transactions) could negatively impact the market price of the company's publicly-traded securities.
• Failure to timely deliver warrant shares upon exercise could result in liquidated damages and potential buy-in costs for the holder.
• Failure to maintain current public information requirements under Rule 144(c) could result in liquidated damages (Public Information Failure Payments) of 2.0% of the aggregate exercise price of the warrants, up to 12% of the aggregate subscription amount.
• The company's obligations to issue shares and warrant shares are unconditional and absolute, regardless of the dilutive effect on other stockholders.

Future Outlook

The company plans to use the net proceeds from the private placement for working capital purposes. It is committed to filing a registration statement for the resale of the issued securities within 45 calendar days and aims to have it effective within 181 days. The company also intends to seek stockholder approval for the issuance of warrant shares and maintain its stock listing.

Management Comments

• The Company will use the net proceeds for working capital purposes.
• The Company agreed to file a registration statement to register the resale by the investors of the Securities as soon as practicable and in any event within 45 calendar days after the date of the Purchase Agreement, to use commercially reasonable efforts to have such registration statement declared effective within 181 days after the closing, and to keep the registration statement effective until no purchaser owns any of the Securities.
• The Company also agreed to use its reasonable best efforts to maintain the listing of the Common Stock and the shares issuable upon exercise of the Common Warrants and Pre-Funded Warrants on the applicable trading market.

Industry Context

StockSavvy.ai notes that securing additional capital through private placements is a common strategy for biotechnology companies like Brainstorm Cell Therapeutics, which often require significant funding for research, development, and operational expenses. The increase in the stock incentive plan pool is also typical for growth-oriented companies to attract and retain talent, though it can lead to shareholder dilution.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the private placement and the increased stock incentive plan pool. The capital raise provides funds for operations, which could stabilize the company, but at a cost of equity.
• Employees/Management: The increased stock incentive plan pool provides more equity compensation opportunities, potentially aiding in talent attraction and retention.
• Investor (Accredited Investor): Gains equity and warrant positions at a discounted price, with mechanisms to manage beneficial ownership and rights to registration for resale.

Next Steps

• Company to file a registration statement for the resale of securities within 45 calendar days after February 24, 2026.
• Company to use commercially reasonable efforts to have the registration statement declared effective within 181 days after February 24, 2026.
• Company to keep the registration statement effective until the investor no longer owns any securities.
• Company to use reasonable best efforts to maintain the listing of its common stock and shares issuable upon exercise of warrants on the applicable trading market.
• Company to call a stockholder meeting within 90 days of February 24, 2026, to obtain Stockholder Approval for the issuance of warrant shares, and subsequent meetings every 90 days if approval is not obtained.
• Up to seven additional closings for the private placement, totaling $875,000, with the final closing by September 25, 2026.

Key Dates

Recommendation

The capital raise provides essential working capital for Brainstorm Cell Therapeutics, which is a positive for continued operations. However, the significant dilutive nature of the private placement, coupled with the substantial increase in the stock incentive plan pool, creates downward pressure on existing shareholder value. While the company has secured funding, the terms suggest a need for capital that comes at a cost to current equity holders. Investors should hold to monitor the effective use of the raised capital and the impact of future dilution, awaiting clearer signs of operational progress or improved financial health before making further investment decisions.

Keywords

Brainstorm Cell Therapeutics, BCLI, Private Placement, Securities Purchase Agreement, Common Stock, Pre-Funded Warrants, Common Warrants, Capital Raise, Working Capital, Stock Incentive Plan, Equity Financing, Dilution, SEC Filing, 8-K, Biotechnology